White House reportedly eyeing restrictions to prescription drug advertising
2025-06-17 11:17:27 ET
More on AbbVie, Eli Lilly, etc.
- Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
- AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow
- Novo Nordisk: An Elite Company That Prints Money
- Lilly-Verve deal sends gene editing stocks higher
- Dividend stocks and ETFs draw attention as Middle East tensions continue
Read the full article on Seeking Alpha
For further details see:
White House reportedly eyeing restrictions to prescription drug advertisingNASDAQ: OTSKF
OTSKF Trading
0.0% G/L:
$67.105 Last:
107 Volume:
$67.105 Open:



